No Picture
News

Poised for Significant Growth and Profitability, BioMarin Shares Company Highlights During R&D Day on November 14th in New York

Valoctocogene Roxaparvovec on Track for US and EU Regulatory Submissions by Year EndVosoritide Sustains Height Gain in Phase 2 Study, Phase 3 Topline Results Expected by Year EndNext Two IND Candidates Identified: 3rd Gene Therapy Candidate in Heredita… […]

No Picture
News

Little biotech’s stock flatlines as its followup attempt at a depression drug trial win ends in another defeat

You can add one more depression drug trial to the scrap heap of failed clinical explorations.
VistaGen followed its spring failure for AV-101 as a monotherapy with a followup defeat using the therapy as an adjunctive treatment for major depression, add… […]